14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BZFD vs ABVX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Abivax SA (ABVX) captures the overall head-to-head institutional edge over BuzzFeed, Inc. (BZFD) on higher Unified Composite conviction (42.4/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while BZFD wins 4–2 across the 6-pillar growth and valuation breakdown. BZFD trades at $0.38 (N/M Forward P/E, -17.7% operating margin) versus ABVX at $73.20 (N/M Forward P/E, -6270.4% operating margin).
Composite vs. Pillar Nuance: While BZFD currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. ABVX 42.4/100 HOLD), ABVX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-6270.4% vs. -17.7% operating margin) and revenue trajectory (-6.8% vs. -43.8% YoY).
Technical & Structure Timing Caution: BZFD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BZFD vs ABVX. Trailing 12-month operating profitability (BZFD -17.7% vs ABVX -6270.4%) and valuation multiples (BZFD N/M vs ABVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $7.1B market capitalization and -6270.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BZFD vs ABVX Key Questions & Quantitative Answers
As of Nov 20, 2026, Abivax SA (ABVX) captures the overall head-to-head institutional edge over BuzzFeed, Inc. (BZFD) on higher Unified Composite conviction (42.4/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Options & Positioning), while BZFD wins 4–2 across the 6-pillar growth and valuation breakdown. BZFD trades at $0.38 (N/M Forward P/E, -17.7% operating margin) versus ABVX at $73.20 (N/M Forward P/E, -6270.4% operating margin). Composite vs. Pillar Nuance: While BZFD currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. ABVX 42.4/100 HOLD), ABVX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-6270.4% vs. -17.7% operating margin) and revenue trajectory (-6.8% vs. -43.8% YoY). Technical & Structure Timing Caution: BZFD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABVX leads the Growth & Scale pillar: BZFD posts -43.8% YoY revenue growth and -54.7% YoY earnings growth on $150M TTM revenue (40.5% gross margin, -17.7% operating margin), compared with ABVX at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (100.0% gross margin, -6270.4% operating margin). On trailing 12-month operating scale, BZFD generates $150M in USD-normalized revenue versus $4.7M for ABVX. In operating R&D and SG&A reinvestment, BZFD deploys 58.2% of Rev ($88M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVX.
BZFD screens cheaper on headline valuation multiples. BZFD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-26.2% FCF margin), whereas ABVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BZFD (-123.0% ROE) versus ABVX (-252.3% ROE) capital efficiency.
In options market volatility and institutional positioning, BZFD carries 319.8% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.52β · 192% Vol realized risk). By comparison, ABVX carries 76.9% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.